Form 4: Galectin Therapeutics Director Acquires Shares, Options

Richard E. Uihlein, a Director and 10% owner of Galectin Therapeutics, acquired 13,158 restricted common shares and 60,000 stock options.

Summary

• Richard E. Uihlein, a Director and 10% Owner of Galectin Therapeutics Inc. (GALT), reported the acquisition of securities.
• On January 16, 2026, Mr. Uihlein acquired 13,158 restricted common shares at a price of $3.04 per share.
• These restricted shares were issued in lieu of a cash retainer and meeting fees totaling $40,000 for 2026, with restrictions lapsing at a rate of 25% at the end of each calendar quarter in 2026.
• Following this transaction, Mr. Uihlein directly beneficially owns 10,332,676 common shares.
• Mr. Uihlein also indirectly beneficially owns 27,710 common shares through the Ed Uihlein Family Foundation, where he serves as president and director.
• Additionally, on January 16, 2026, Mr. Uihlein acquired 60,000 stock options with an exercise price of $3.04 per share, expiring on January 16, 2036.
• These stock options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and will vest 100% on December 31, 2026.
• Following this transaction, Mr. Uihlein directly beneficially owns 60,000 stock options.

Sentiment

Score: 7

Explanation: The acquisition of additional shares and stock options by a director and significant owner, as part of an equity incentive plan, indicates continued alignment of interests and confidence in the company's future.

Positives

• A director and significant owner, Richard E. Uihlein, acquired additional equity in the company, aligning his interests further with shareholders.
• The acquisition of restricted shares and stock options is part of an equity incentive plan, demonstrating a commitment to long-term performance.

Future Outlook

The acquired stock options are set to vest 100% on December 31, 2026, and the restrictions on the common shares will lapse quarterly throughout 2026, indicating a forward-looking compensation structure tied to future performance and retention.

Management Comments

• Management has opted to receive a portion of their 2026 compensation in equity, specifically 13,158 restricted shares in lieu of $40,000 cash, aligning their financial incentives with the company's stock performance.

Industry Context

This filing represents a routine insider transaction related to executive compensation, which is a common practice across various industries to align the interests of management with those of shareholders. It does not directly reflect broader industry trends or competitive positioning.

Corporate Governance

Related Party Transactions

• Richard E. Uihlein indirectly beneficially owns 27,710 common shares through the Ed Uihlein Family Foundation, where he is president and director, sharing voting and dispositive power.

Stakeholder Impact

• Shareholders: Increased insider ownership can be viewed positively as it aligns management's financial interests with shareholder returns.
• Employees: The use of an equity incentive plan for a director may signal a broader commitment to performance-based compensation across the organization.

Next Steps

• Restrictions on the 13,158 common shares will lapse at a rate of 25% at the end of each calendar quarter in 2026.
• The 60,000 stock options will vest 100% on December 31, 2026.

Key Dates

Recommendation

The Form 4 filing details a routine compensation event for a director, involving the acquisition of restricted stock and stock options as part of an established equity incentive plan. While insider acquisitions can be a positive signal, this transaction does not represent a discretionary open-market purchase that would typically warrant a 'buy' recommendation based solely on this filing. It primarily serves to align the director's interests with shareholders, reinforcing a 'hold' stance.

Keywords

Galectin Therapeutics, GALT, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock, Equity Incentive Plan, Director Acquisition, Beneficial Ownership